Author: R1 Therapeutics

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

June 30, 2026
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

March 17, 2026

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease